Science Foundation Arizona (SFAz) encourages Community College Hispanic Serving Institutions (HSIs) that meet eligibility requirements to apply for Cohort 3 of the KickStarter Program with support by National Science Foundation (NSF HRD# 1450061).
It is well-recognized that patients receiving carboplatin as second-line treatment of ovarian. cancer have at least a modest risk for experiencing hypersensitivity reactions.1 The onset of. reactions is unpredictable and they could occur immediately upon initiation of the drug infusion. or may not be seen until one half or more of the infusion has been administered to the patient. On the other hand, the onset of the reactions has also been reported in patients receiving more. than six cumulative courses. The symptoms associated with the reactions range from a minor. rash to diffuse erythroderma, pruritis, severe anxiety, dyspnea, tachycardia, hypotension, and in. severe cases, death.
Breast milk jaundice occurs later in the newborn period, with the bilirubin level usually peaking in the sixth to 14th days of life. This late-onset jaundice may develop in up to one third of healthy breastfed infants. 1 Total serum bilirubin levels vary from 12 to 20 mg per dL (340 Î¼ mol per L) and are nonpathologic., 3, 10 In the term newborn with hemolysis, a bilirubin level above 20 mg per dL (342 Î¼ mol per L) is a concern. 1, 3. The effects of bilirubin toxicity are often devastating and irreversible (Table 2) . 3, 9 Early signs of kernicterus are subtle and nonspecific, typically appearing three to four days after birth.